US survey highlights gene patent pitfalls
This article was originally published in Clinica
A US team believes it has uncovered the first evidence to support growing concern that the commercialisation of molecular genetic discoveries could place limitations on clinical practice. In a commentary published in Nature (February 7), the researchers report that US laboratories have discontinued clinical genetic-testing services for haemochromatosis because of the cost of the patent.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.